James Cardi, MD
Internal Medicine · Cranston, RINPI 1104890292
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,643 of the $3,503 with a category attached, or 75.4%. It is spread thinly across 22 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,564 and has fallen 88.9% since, to $173 in 2025. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$706
- AbbVie$347
- Johnson & Johnson$322
- Boehringer Ingelheim$310
- AstraZeneca$285
- Teva Pharmaceuticals USA, Inc.$271
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,64375%
- Education$1003%
- Gifts$542%
- Other$70620%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 2 | $706 |
| AbbVie | 18 | $347 |
| Johnson & Johnson | 21 | $322 |
| Boehringer Ingelheim | 16 | $310 |
| AstraZeneca | 11 | $285 |
| Teva Pharmaceuticals USA, Inc. | 29 | $271 |
| GSK | 11 | $190 |
| Indivior Inc. | 9 | $177 |
| Astellas Pharma US Inc | 7 | $175 |
| Pfizer | 16 | $164 |
| Lilly USA, LLC | 7 | $112 |
| Exact Sciences | 4 | $95 |
| Phathom Pharmaceuticals, Inc. | 1 | $83 |
| Welch Allyn | 1 | $54 |
| Novo Nordisk | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $34 |
| Novartis | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
How this compares
$3,503 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $70,135 |
| JardianceEmpagliflozin | 85 | $69,016 |
| EliquisApixaban | 78 | $51,472 |
| XareltoRivaroxaban | 30 | $23,129 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 79 | $18,575 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $14,600 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $12,847 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $11,818 |
| JanuviaSitagliptin Phosphate | 14 | $8,113 |
| Diclofenac Sodium | 13 | $7,438 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,391 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $5,087 |
| Atorvastatin Calcium | 395 | $4,344 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,995 |
| Buprenorphine Hcl | 38 | $3,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $41 | $70,13575 claims |
| Boehringer IngelheimJardiance | $310 | $69,01685 claims |
| PfizerEliquis | $164 | $51,47278 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta | $190 | $34,83872 claims |
| Johnson & JohnsonXarelto | $322 | $23,12930 claims |
| Indivior Inc.Suboxone | $177 | $11,81817 claims |
| AstraZenecaSymbicort | $285 | $3,99517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Cranston
- Gregory AllenCranston$38K
- Joseph CampbellCranston$13K
- Dennis BotelhoCranston$12K
- Stephen BeaupreCranston$8K
- Usha PanneerselvamCranston$7K
- Olga TverskayaCranston$6K
- Leah AdamsCranston$4K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.